Physician profile
Brian E Michael
NPI 1942237722
$63,045.79
in general payments reported to CMS, 2019-2025
56 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,950 · 2020: $3,976 · 2021: $3,396 · 2022: $3,982 · 2023: $18K · 2024: $15K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Honoraria: $12K · Food and Beverage: $11K · Travel and Lodging: $7,300 · Consulting Fee: $3,600 · Education: $18.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,800.00 |
| Honoraria | $12,450.00 |
| Food and Beverage | $10,573.66 |
| Travel and Lodging | $7,299.90 |
| Consulting Fee | $3,600.00 |
| Education | $18.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24,961.33 | 2019-2025 | Tepezza, Repatha, Evenity |
| Horizon Therapeutics Plc | $19,721.69 | 2019-2023 | Tepezza |
| Corcept Therapeutics | $3,261.60 | 2019-2024 | Korlym |
| Novo Nordisk INC | $2,573.97 | 2019-2025 | Sogroya, Wegovy, Ozempic |
| Abbvie INC. | $2,217.93 | 2019-2025 | |
| Lilly USA, LLC | $1,489.50 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Tandem Diabetes Care, INC. | $996.45 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $843.07 | 2019-2025 | |
| Cequr Corporation | $661.20 | 2021-2025 | Cequr Simplicity |
| Dexcom, INC. | $565.58 | 2021-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $497.70 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $464.62 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $453.04 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.03 | 2019-2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $261.70 | 2021-2025 | Unithroid |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $259.30 | 2021-2025 | Nexletol |
| Antares Pharma, INC. | $252.50 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Radius Health, INC. | $229.61 | 2023-2025 | Tymlos |
| Sandoz INC. | $229.47 | 2021-2024 | Omnitrope |
| Ibsa Pharma INC. | $225.04 | 2021-2025 | Tirosint, Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $205.88 | 2019-2022 | |
| Pfizer INC. | $198.29 | 2019-2024 | |
| Opko Pharmaceuticals, LLC | $175.88 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $166.42 | 2021-2025 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $148.55 | 2022-2025 | Strensiq |
| Insulet Corporation | $148.40 | 2020-2025 | Omnipod |
| Valeritas, INC. | $138.69 | 2019 | |
| Ascendis Pharma Endocrinology INC | $113.42 | 2024-2025 | Yorvipath |
| Zealand Pharma US, INC. | $88.82 | 2021-2022 | |
| Amarin Pharma, INC. | $78.02 | 2020-2022 | |
| Kyowa Kirin, INC. | $71.72 | 2024-2025 | Crysvita |
| Beta Bionics, INC. | $70.49 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Eton Pharmaceuticals, INC. | $69.78 | 2023 | Alkindi |
| Eisai INC. | $63.87 | 2023-2025 | |
| Medtronic, INC. | $62.99 | 2021-2025 | Inceptiv, Minimed 780g |
| Novartis Pharmaceuticals Corporation | $55.38 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $53.77 | 2021-2023 | Crysvita |
| Abbott Laboratories | $53.77 | 2021-2023 | Freestyle Libre 3 |
| Ipsen Biopharmaceuticals, INC | $51.13 | 2021-2022 | |
| Sequel Med Tech, LLC | $48.13 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $48.06 | 2019-2020 | |
| Tolmar, INC. | $47.69 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $43.94 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.19 | 2020-2021 | |
| Halozyme INC | $33.29 | 2023 | |
| Bigfoot Biomedical INC | $31.44 | 2022 | |
| Amryt Pharma Holdings LTD | $31.04 | 2022-2023 | Juxtapid |
| Azurity Pharmaceuticals, INC. | $22.18 | 2025 | Triptodur |
| Clarus Therapeutics INC. | $20.48 | 2021 | |
| Acella Pharmaceuticals, LLC | $18.30 | 2025 | NP Thyroid 60 |
| Rhythm Pharmaceuticals, INC. | $17.69 | 2025 | Imcivree |
| Medtronic Minimed, INC. | $16.75 | 2020 | |
| Eusa Pharma (US) LLC | $16.71 | 2022 | |
| Madrigal Pharmaceuticals | $16.50 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $14.44 | 2020 | |
| Tempus Ai, INC | $14.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.